

AMENDMENTS TO THE CLAIMS:


This listing of claims will replace all prior versions,
and listings, of claims in the application:

LISTING OF CLAIMS:

1-18 (canceled)

19. (new) A compound of the following formula (I)

:




(I)

wherein:


- n_1, n_2, n_3 and n_4 , independently from each other, represent an integer from 1 to 5,
- R_1, R_2, R_3 and R_4 , independently from each other, represent :

- . -COOH,
- . -PO(OH)₂,



wherein n_5 represents an integer from 1 to 5, R_5 represents -COOH or -PO(OH)₂, and Y represents H or a group -(CH₂)_{n_6}-R₆ in which n_6 represents an integer from 1 to 5, and R_6 represents -COOH or -PO(OH)₂,

provided that at least one of R_1 , R_2 , R_3 or R_4 represents a group





wherein,

- R represents :

- . H, or -NHCOCH₃, or
 - . a group carrying a function liable to bind, if necessary via a binding site, to molecules which are able to bind specifically with epitopes located at the surface of the cells of the organism, or to chemical or biological compounds located at the surface of a solid carrier, or

- . a group carrying a function linked, if necessary via a binding site, and wherein

the two following compounds, cyclohexyl diethylenetriamine pentacetic acid (CDTPA) and cyclohexyl triethylenetetraamine hexaacetic acid (CTTHA), are excluded:




CTTHA

20. (new) The compound according to claim 19,


wherein:

- when R_1 , R_2 , R_3 or R_4 represents $-\text{COOH}$ or $-\text{PO}(\text{OH})_2$, then n_1 , n_2 , n_3 or n_4 represents 1 respectively,
- when R_1 , R_2 , R_3 or R_4 represents a group



then n_1 , n_2 , n_3 or n_4 represents 2 or 3 respectively, and - n_5 , and optionally n_6 , represents 1.


21. (new) The compound according to claim 19, wherein at least one of R_1 , R_2 , R_3 and R_4 , represent a group



22. (new) The compound according to claim 19, wherein R is a group coupled to a vector or solid support binding.


23.. (new) The compound according to claim 19, wherein R represents a group carrying a function linked, if necessary via a binding site, to antibodies, haptens or peptides.

24. (new) A compound of the following formula (III) :




(III)

in which R₁, R₂, R₃, R₅ and R₆ independently from each other represent -COOH or -PO(OH)₂, and R is H, or -NHCOCH₃ or a group carrying a function liable to bind, if necessary via a binding site to molecules, which are able to bind specifically with epitopes located at the surface of the cells of the organism, or to chemical or biological compounds located at the surface of a solid carrier, or a group carrying a function linked, if necessary via a binding site, and wherein the following compounds CDTPA and CTTHA are excluded:



, and




CTTHA

25. (new) The compound according to claim 24, of formula (III) wherein :


- . R₁ = R₅ = R₆ = COOH and R₂, = R₃ = PO(OH)₂, or
- . R₁ = R₂ = R₃ = R₅ = R₆ = COOH, or
- . R₁ = R₂ = R₃ = R₅ = R₆ = PO(OH)₂.

26. (new) The compound according to claim 19, having the following formula (IV) :




(IV)

wherein R₂, R₅ and R₆, independently form each other, represent -COOH or -PO(OH)₂, and R is H, or -NHCOCH₃, or a group carrying a function liable to bind, if necessary via a binding site to molecules, which are able to bind specifically with epitopes located at the surface of the cells of the organism, or to chemical or biological compounds located at the surface of a solid carrier, or a group carrying a function linked, if necessary via a binding site, and wherein the following compounds CDTPA and CTTHA are excluded:



, and



CTTHA

27. (new) The compounds according to claim 8 of formula (IV) wherein :

- . $R_2 = R_3 = PO(OH)_2$, and $R_5 = R_6 = COOH$, or
- . $R_2 = R_3 = R_5 = R_6 = COOH$, or
- . $R_2 = R_3 = R_5 = R_6 = PO(OH)_2$.

28. (new) A complex comprising the compound according to claim 19, and a radioactive element.

29. (new) The complex according to claim 28, wherein said radioelements are α or β emitter radiometals.


30. (new) A method for the manufacture of a medicament for radioimmunotherapy, comprising adding a complex according to claim 28 to said medicament.

31. (new) A Pharmaceutical composition comprising a complex according to claim 28, and a suitable pharmaceutical carrier.

32. (new) The complex according to claim 28, wherein the radioelements are $\gamma\alpha$ emitter radiometals.

33. (new) A method for carrying out radioimmunoscintigraphy in a subject, comprising administering the complex according to claim 28 to said subject.

34. (new) A compound of the following formula (I) :




(I)


wherein:

- n_1, n_2, n_3 and n_4 , independently from each other, represent an integer from 1 to 5,
- $\text{R}_1, \text{R}_2, \text{R}_3$ and R_4 , independently from each other, represent :

- . -COOH,
- . -PO(OH)₂,



wherein n_5 represents an integer from 1 to 5, R_5 represents -COOH or -PO(OH)₂, and Y represents H or a group -(CH₂)_{n₆}-R₆ in which n_6 represents an integer from 1 to 5, and R_6 represents -COOH or -PO(OH)₂, provided that at least one of R_1 , R_2 , R_3 or R_4 represents a group



wherein,

- R represents :

- . H, or -NHCOCH₃, or
- . a group carrying a function liable to bind, if necessary via a binding site, to molecules which are able to bind specifically with epitopes located at the surface of the cells of the organism, or to chemical or biological compounds located at the surface of a solid carrier, or
- . a group carrying a function linked, if necessary via a binding site.

35. (new) A method for treating inflammation and/or pain, ionic imbalances, or the formation of stones

in an organism, comprising administering to an organism in need of treatment thereof a compound according to claim 34.

36. (new) A method for carrying out a process for the detoxication of polluted medium, comprising adding the compound according to claim 28 to said medium.

37. (new) A method for carrying out a process for radionuclide purification in a medium, comprising adding a compound according to claim 34 to said medium.

38. (new) A method for carrying out a bone scintigraphy, comprising administering to an organism a compound according to claim 34.